Dr. Tracy Tsuetaki Joins Parexel As Senior Vice President Of Peri/Post-Approval Services And PAREXEL Consulting

BOSTON, Sept. 4, 2014 /PRNewswire/ -- PAREXEL International Corporation PRXL, a leading global biopharmaceutical services provider, today announced the appointment of Dr. Tracy Tsuetaki as Senior Vice President for Peri/Post-Approval Services and PAREXEL Consulting.  He will oversee the strategy and operational management for both businesses.  He will also serve on PAREXEL's Business Review Committee, the Company's senior-most leadership team, and assist in developing and implementing PAREXEL's strategic objectives.

"In a competitive, global environment, customers are increasingly seeking to accelerate drug development and build market presence," said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL.  "Dr. Tsuetaki brings deep and wide-ranging industry experience that will strengthen our ability to deliver innovative peri- and post-approval services and consulting to the industry."

Dr. Tsuetaki joins PAREXEL from UnitedHealth Group, where he served as Group President for Optum Life Sciences. In that role, he managed the Strategic Regulatory and Safety Services organization.  This encompassed pharmacovigilance, medical information, pharmacoepidemiology, risk evaluation, and risk mitigation strategies.  It also included regulatory affairs consulting and operations outsourcing, Chemical Manufacturing and Control (CMC), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP) services. Prior to this role, he was Group President of i3, Inc. - Clinical Development Services, also at United Healthcare Group.  He led Phase I-III clinical research and strategic regulatory offerings, as well as resourcing and staffing services. His expertise also includes international leadership of medical communications, post-marketing and reimbursement business lines. 

"PAREXEL is recognized for its global expertise across the clinical-development spectrum, including late phase services and consulting," said Dr. Tsuetaki.  "In particular, the Company has demonstrated leadership through its new regulatory outsourcing services.  I look forward to further building these offerings to help customers address their post-marketing and regulatory requirements."

Dr. Tsuetaki holds a B.S. in nutritional science from the University of California at Davis, a doctorate in optometry and a M.S. in physiological optics from the University of California at Berkeley, and an MBA from Northwestern University's Kellogg Graduate School of Management.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 80 locations in 51 countries around the world, and has approximately 15,560 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and "Your Journey.  Our Mission." are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 as filed with the SEC on August 20, 2014, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:
Diana Martin, Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com

Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation